Time-of-day immunochemotherapy in nonsmall cell lung cancer: a randomized phase 3 trial
“In summary, our study indicates that early ToD immunochemotherapy substantially improves PFS and OS and is associated with enhanced antitumor CD8+ T cell characteristics compared with late ToD treatment.”
Lightweight Neural Networks Improve Lung Cancer Diagnosis
“The findings highlight the potential of custom lightweight CNN architectures as efficient tools for histopathological image analysis. By offering a reproducible evaluation framework, this approach may be extended to larger datasets or adapted for future clinical diagnostic applications, supporting the integration of artificial intelligence into routine healthcare practice.”
Deep-Learning CT Biomarker Predicts Survival Better Than Traditional Measures in Immunotherapy-Treated Advanced NSCLC
“The investigators concluded, “Serial CTRS is an externally validated, fully automated, deep-learning, serial imaging–based biomarker that leverages routine CT scans from baseline and early-response follow-up to predict overall survival more effectively than RECIST and tumor volume change in immune checkpoint inhibitor–treated patients with advanced NSCLC. The automated design of Serial CTRS facilitates future integration into clinical practice and clinical trial workflows. With further validation across therapeutic modalities, Serial CTRS has the potential to enable more accurate, early treatment readouts in both clinical practice and clinical trial settings.””
POM121 O-GlcNAcylation facilitates bone metastasis in non-small cell lung cancer through enhanced c-MYC nuclear import and ECM reprogramming
“These findings establish the OGT-POM121-c-MYC-ECM axis as a potential diagnostic biomarker and a promising therapeutic target for NSCLC bone metastasis.”
NCCN NSCLC Guidelines Update Staging, Emphasize Molecular Testing
“The National Comprehensive Cancer Network’s (NCCN) newly updated non-small cell lung cancer (NSCLC) guidelines add sevabertinib as a treatment option for some patients with advanced disease, make datopotamab deruxtecan-dlink a preferred option for some patients in second line, and update staging guidelines to follow the American Joint Committee on Cancer (AJCC) 9th edition.”
Additional lymph node evaluation needed during surgery to accurately identify lung cancer spread
“Breakthrough research presented at the 2026 Society of Thoracic Surgeons Annual Meeting shows that additional lymph node evaluation is needed during surgery for non-small cell lung cancer (NSCLC) to accurately identify cancer spread.”
Pirfenidone Associated With Over 70% Lower Lung Cancer Risk in IPF
“Pirfenidone may reduce lung cancer risk in IPF by up to 76% in sensitivity analyses, though evidence is limited to observational East Asian studies.”
‘Staggering’: More than 60% of patients with lung cancer do not meet screening criteria
“Key takeaways: Lung cancer screening guidelines may exclude more than 60% of patients who develop the disease. Age-based screening could save more than 25,000 additional lives per year.”
Monoclonal Antibody May Transform Care for Certain NSCLC, Phase 3 Data Suggest
“Gotistobart reduced risk for death by nearly half compared with docetaxel in patients with metastatic squamous non-small cell lung cancer (NSCLC) who had progressed on PD-(L)1 inhibitors. These results are based on findings from stage 1 of the ongoing, multicenter, international, randomized controlled phase 3 PRESERVE-003 trial and were presented at the North America Conference on Lung Cancer (NACLC). Stage 1 is the dose-confirming part of the trial, and stage 2 is actively enrolling patients.”
NHS launches a single end-to-end lung cancer diagnostic pathway initiative with Optellum
“This is the first NHS programme to combine VNC’s AI-based lung nodule risk stratification with robotic-assisted bronchoscopy, streamlining the pathway from CT imaging to biopsy for patients with suspected lung cancer. With VNC’s AI, high-risk lung nodules on imaging are rapidly identified, and if tissue sampling is required, robotic-assisted bronchoscopy is then used to navigate to and biopsy hard-to-reach nodules as small as 6 mm. For many patients, this can potentially reduce months of uncertainty with a single targeted procedure.”
Foot on the gas: How RIT1 and YAP accelerate lung adenocarcinoma
“Mutations in the RIT1 gene have emerged as rare, yet recurrent drivers in several human cancers, including lung adenocarcinoma. RIT1 (Ras-like in all tissues) encodes a protein that helps cells respond to growth signals from their environment. It works a bit like a rechargeable battery: when it’s loaded with energy, it sends messages that tell a cell to grow or adapt, and once that energy is spent, the signal shuts off.”
Leptomeningeal Metastasis (LM) Clinical Trial Offers Treatment for Stage 4 Lung Cancer Patient
“Carlos Veras had been given months to live, when his stage 4 lung cancer spread to the fluid around his brain and spine. He’s alive two years later, thanks to a collaboration between neuro-oncologist Dr. Adrienne Boire, left, and computational biologist Dr. Dana Pe’er. After a decade of research, the scientists found a way to stop the cancer cells from surviving in the cerebrospinal fluid.”
Lung cancer survivors at risk for non-lung secondary cancer years after definitive therapy
“Key takeaways: Non-lung secondary cancers can develop in survivors of lung cancer years after completion of definitive therapy. Hereditary cancer syndrome and/or pathogenic germline variants were strongly associated with increased risk.”
Treatment adherence and clinical outcomes of osimertinib in minority patients with advanced EGFR mutated NSCLC
“In multivariable analyses, NHB patients experienced significantly worse overall survival compared with NHW patients, both in the overall cohort (Hazard ratio (HR) 1.83, 95% confidence interval (CI) 1.02–3.27) and in first-line osimertinib users (HR 3.42, 95% CI 1.48–7.88), despite similar adherence rates. Hispanic and Asian patients also showed trends toward inferior outcomes. These findings highlight survival disparities and underscore the need for inclusive trials and targeted strategies.”
Phytochemical Triad in Lung Cancer: Synergistic Mechanisms and Clinical Translation of Genistein, Piperine, and Resveratrol
“This review critically explores their synergistic effects while highlighting the challenges in translating these findings into clinical applications for lung cancer. By elucidating the underlying molecular mechanisms and therapeutic synergy, these natural compounds emerge as promising adjuncts for lung cancer therapy, warranting further mechanistic and clinical investigation.”
